Dr Eytan Ellenberg, MD, MPH, PhD, Head of Research & Academy, Office of Medical Affairs, National Insurance, Institute of Israel.
Founder, Fair Research Organization (FRO), Jerusalem, Israel.
Individual-level attribution modeling reveals that real-world semaglutide effectiveness is not a fixed property of the molecule, but an interaction between pharmacological exposure and modifiable care and support conditions, carrying implications for real-world evidence interpretation and clinical development.
Pharmacovigilance has advanced in detecting population-level safety signals, but a critical gap remains in translating those insights into transparent, defensible patient-level decisions.
